



Bayer Provides Product Supply Update on Xofigo® (radium Ra 223 dichloride) Injection

Whippany, NJ, October 17, 2014 - Bayer HealthCare is currently experiencing a drug shortage of Xofigo (radium Ra 223 dichloride) Injection due to a production issue. Through the standard inspection process, Bayer determined that recently produced drug product did not meet the high quality standards, due to small fibrous particles found in some of the vials. Therefore, this drug product was not distributed. An expert team is working diligently to resolve this matter. At this time, Bayer is unable to anticipate when distribution of Xofigo can be resumed.

Bayer is in regular communications with physicians and clinical trial investigators to provide information on Xofigo supply availability.

Bayer is working closely with the U.S. Food and Drug Administration (FDA) on this matter. All previously released product met the quality standards in place for Xofigo.

Bayer is committed to ensuring patient access to Xofigo and we are working to restore supply as quickly as possible.

For further information, patients should contact their healthcare professionals or the Bayer Call Center at 1-888-84-Bayer, or 1-888-842-2937.